Skip to content

Clinical trials

Acquired Immunodeficiency Syndrome trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Acquired Immunodeficiency Syndrome Country / region: China Clear all

87 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20053
20081
20098
20101
20111
20124
20132
20143
20152
20163
20179
20187
20197
20205
20214
20225
20238
20245
20252
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status35
Completed32
Recruiting12
Not yet recruiting5
Active, not recruiting2
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Guangzhou 8th People's Hospital11
National Center for AIDS/STD Control and Prevention, China CDC6
Peking Union Medical College Hospital6
Shanghai Public Health Clinical Center6
First Affiliated Hospital of Zhejiang University4
Jiangsu Aidea Pharmaceutical Group Co., Ltd.4
Frontier Biotechnologies Inc.3
Guang'anmen Hospital of China Academy of Chinese Medical Sciences3
Henan Genuine Biotech Co., Ltd.3
AbbVie2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Acquired Immunodeficiency Syndrome87
HIV Infections15
Infections5
Pneumonia3
Cardiovascular Diseases2
Coinfection2
Fibrosis2
Hepatitis C2
Hepatitis C, Chronic2
Non-alcoholic Fatty Liver Disease2

Trials

Showing 1 to 25 of 87. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.